Tada,

I agree. No disappointment. BETonMACE was a cardio outcomes trial so it makes sense for it to be first presented at a cardio conference like AHA. Kind of awkward timing with ASN happening the week before. You might be right that AHA embargo impacts the ability to present the previous week at ASN. There was one abstract on the ASN late breaker list that was withdrawn. No idea if it was BETonMACE or Resverlogix related but if so perhaps it was withdrawn due to AHA embargo. I had some hope that the CKD sub-study was different enough from the primary outcome that there was no embargo conflict. And we don't even know for sure if they even applied to present the CKD sub-study at ASN. Tick tock.

BearDownAZ